Capsule summary Despite the absence of robust evidence, tacrolimus is quite commonly used off label as maintenance treatment for seborrheic dermatitis, in clinical practice. Tacrolimus 0.1% ointment applied twice a …
Topical anti-microbial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild-to-moderate atopic dermatitis in a phase 2 randomized controlled trial.
Dysbiosis and colonization with Staphylococcus aureus is considered to play an important role in the pathogenesis of atopic dermatitis (AD). Recovering this dysbiosis may improve AD symptoms. Omiganan is a …
Cutaneous toxicities in melanoma patients receiving checkpoint inhibitor therapy, a retrospective review: The experience of a single large specialist institution.
CPI was approved by the European Medicines Agency (EMA) in 2012 for advanced melanoma and extended to include adjuvant melanoma treatment in 2018. Expectation for survival in advanced melanoma now …
Comparison of efficacy of noncultured hair follicle cell suspension and noncultured epidermal cell suspension in repigmentation of leukotrichia and skin patch in vitiligo: a randomized trial.
Vitiligo manifests as hypo- to de-pigmented macules, which are sometimes associated with leukotrichia. For complete cosmetic improvement, the repigmentation of leukotrichia is an important component.This randomized controlled trial included patients …
Dupilumab treatment ameliorates clinical and hematological symptoms, including blood eosinophilia, in patients with atopic dermatitis.
Atopic dermatitis (AD) is an allergic disease that affects individuals of various ages. Recently, the IL-4/13 inhibitor dupilumab has gained regulatory approval for clinical use in AD patients. Dupilumab has …
Immunotherapy Combo Treats Advanced Kidney Cancer
First results show survival benefit with nivolumab plus cabozantinib versus sunitinib
Ductal Carcinoma In Situ Tied to Threefold Higher Risk for Death
Risk for dying from breast cancer remains elevated 15 years after initial diagnosis
Mortality Below 40 Percent for COVID-19 Patients Put on ECMO
Cumulative incidence of in-hospital mortality estimated to be 37.4 percent at 90 days
Considerable State-Level Variation Found in Prevalence of Eclampsia
Variation between states modest in chronic hypertension, hypertensive disorders of pregnancy
Antibodies Decrease With Time After COVID-19 Symptom Onset
For all donors of convalescent plasma, drop seen in anti-RBD antibody levels from first to last donation